Reminder: Roche Virtual Event – Update following ASH 2022 Wednesday 14th December 2022 Mittwoch, 07. Dezember 2022 - 15:07

We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 14 December 2022, highlighting Roche data presented at the American Society of Hematology 2022 Meeting and Exposition, from 10th to 13th December.

16:00 – 17:30 CET / 15:00 - 16:30 GMT

10:00 – 11:30 am EST / 7:00 – 8:30 am PST

Agenda

• Welcome - Bruno Eschli, Head of Investor Relations
• Hematology franchise overview - Peter Ahnesorg, Franchise Head Hematology
• Review of key clinical data presented at ASH - Charles Fuchs, Senior Vice President - Global Head of Oncology and Hematology Product Development
• Spark Therapeutics, Inc. (SPK-8011) clinical data update - Gallia G. Levy, MD, PhD, Chief Medical and Product Strategy Officer

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.
> click here

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Loren Kalm

Head of Investor Relations, North America

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com